Seres Therapeutics Inc. (MCRB)
8.03
0.55 (7.32%)
At close: Apr 22, 2025, 11:51 AM
7.32% (1D)
| Bid | n/a |
| Market Cap | 1.4B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 136K |
| EPS (ttm) | -16.2 |
| PE Ratio (ttm) | -0.5 |
| Forward PE | -1.54 |
| Analyst | Hold |
| Ask | n/a |
| Volume | 198,862 |
| Avg. Volume (20D) | 53,117 |
| Open | 7.62 |
| Previous Close | 7.48 |
| Day's Range | 7.18 - 8.57 |
| 52-Week Range | 7.18 - 30.60 |
| Beta | 2.53 |
About MCRB
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteri...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 26, 2015
Employees 103
Stock Exchange NASDAQ
Ticker Symbol MCRB
Analyst Forecast
According to 5 analyst ratings, the average rating for MCRB stock is "Hold." The 12-month stock price forecast is $25, which is an increase of 211.33% from the latest price.
Stock ForecastsNext Earnings Release
Seres Therapeutics Inc. is scheduled to release its earnings on May 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
+3.86%
Seres Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
6 months ago
+10.44%
Seres Therapeutics shares are trading higher after the company announced its stockholders voted to approve the previously announced proposed sale of its VOWST business to Société des Produits Nestlé S.A.
